Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 13, 2020 21:40 ET | Source: Altimmune, Inc.

Altimmune Announces Pricing of a Public Offering of $115 Million of Common Stock and Pre-Funded Warrants

GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten...
July 13, 2020 16:01 ET | Source: Altimmune, Inc.

Altimmune Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market...
July 13, 2020 07:00 ET | Source: Altimmune, Inc.

Altimmune and the University of Alabama at Birmingham (UAB) Announce Positive Preclinical Results for Intranasal COVID-19 Vaccine Candidate, AdCOVID™

GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from the preclinical studies of its...
July 09, 2020 07:00 ET | Source: Altimmune, Inc.

Altimmune Signs Teaming Agreement with DynPort Vaccine Company on U.S. Government Funding Efforts for its COVID-19 Vaccine Candidate, AdCOVID™

GAITHERSBURG, Md., July 09, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has entered into a teaming agreement with...
June 30, 2020 07:00 ET | Source: Altimmune, Inc.

Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate

GAITHERSBURG, Md., June 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in the Company’s Phase 1b...
June 29, 2020 07:00 ET | Source: Altimmune, Inc.

Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19

GAITHERSBURG, Md., June 29, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it was awarded $4.7 million from the U.S. Army Medical...
June 22, 2020 07:00 ET | Source: Altimmune, Inc.

Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell™ Immunotherapeutic for the Treatment of Chronic Hepatitis B

GAITHERSBURG, Md., June 22, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
June 01, 2020 07:00 ET | Source: Altimmune, Inc.

Altimmune Launches Clinical Trial of T-COVIDTM, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19

Clearance of IND application received from the U.S. FDAPlanned Phase 1/2 outpatient clinical trial will focus on patients with early SARS-CoV-2 infection Placebo-controlled trial expected to commence...
May 13, 2020 17:18 ET | Source: Altimmune, Inc.

Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update

GAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020...
May 12, 2020 07:00 ET | Source: Altimmune, Inc.

Altimmune Appoints Former Pfizer and GSK Executive Diane Jorkasky, M.D. to its Board of Directors

GAITHERSBURG, Md., May 12, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Diane Jorkasky, M.D. to its Board of...